Toscana Biomarkers

• it
• en

• Company
  • • Investors
    • Management
    • Scientific Board
    • Staff
    • Grants and collaborations
• Research

  • Research

    In the process leading to the commercialization of in vitro diagnostic tests, Toscana Biomarkers is involved in finding serological markers and developing pre-competitive tests.

  • • MS Multiple Sclerosis
    • RA Rheumatoid Arthritis
    • SLE Systemic Lupus Erythematosus
    • NMO Neuromyelitis Optica
    • CU Chronic Urticaria
• Products

  • Products

    Our mission is the identification of specific biomarkers in patients sera in order to set up in vitro assays to support diagnosis and therapeutic treatments.

  • • Biomarkers
    • Diagnostic test
• Support
  • • Literature and Patents
• Technology

• Contacts
• News

Home > Research > NMO - Neuromyelitis Optica

NMO - Neuromyelitis Optica

Neuromyelitis optica (NMO) is an autoimmune inflammatory demyelinating disease, thought to be completely different from MS owing to the recent discovery of aquaporin-4 (AQP4) as the main target antigen.

Currently, five different diagnostic techniques are used: indirect immunofluorescence, cell-based assays, radio-immunoprecipitation and fluorine-immunoprecipitation assays, ELISA based on the use of the AQP4 protein, recombinant or extractive.

Toscana Biomarkers is working on the selection of new antigenic molecules for the diagnosis of NMO using the chemical reverse approach already successfully applied to the development of other immunoassays. This project is supported through funds granted by Regione Toscana (August 2010) .